LY 333531 hydrochloride
Cat. No. 4738
Alternative Name: Ruboxistaurin
Chemical Name: (9S)-9-[(Dimethylamino)methyl]-6,7,
Biological ActivityIsozyme-selective inhibitor of protein kinase C (PKC); competitively and reversibly inhibits PKCβI and PKCβII (IC50 values are 4.7 and 5.9 nM respectively). Selective for PKCβ over other PKC isozymes (IC50 values are 0.052, 0.25, 0.30, 0.36, 0.60 and >100 μM for PKCη, -δ, -γ, -α, -ε and -ζ respectively). Exhibits selectivity for PKC over other ATP-dependent kinases, including protein kinase A, casein kinase and src).
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
Faul et al (2003) Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCβ. Bioorg.Med.Chem.Lett. 13 1857. PMID: 12749884.
Samokhin et al (1999) Effects of protein kinase C inhibitors on thromboxane production by thrombin-stimulated platelets. Eur.J.Pharmacol. 386 297. PMID: 10618482.
Jirousek et al (1996) (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16,21-dimetheno-1H,13H-dibenzo[e,k]]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-dione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase Cβ. J.Med.Chem. 39 2664. PMID: 8709095.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products. Selected citations for LY 333531 hydrochloride include:
Muellner et al (2015) Targeting a cell state common to triple-negative breast cancers. ASN Neuro 11 789. PMID: 25699542.
Do you know of a great paper that uses LY 333531 hydrochloride from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: LY 333531 hydrochloride, supplier, LY333531, hydrochloride, Ruboxistaurin, protein, kinase, c, PKC, PKCb, isozymes, selective, PKCBI, PKCbetaI, PKCβI, PKCBII, PKCbetaII, PKCβII, PKCB1, PKCbeta1, PKCβ1, PKCB2, PKCbeta2, PKCβ2, inhbitors, inhibits, Tocris Bioscience, Protein Kinase C Inhibitor products
Find multiple products by catalog number
New Products in this Area
Selective non-ATP competitive inhibitor of GSK 3βBI 605906
Selective IKKβ inhibitorGSK 319347A
Potent and selective IKKε inhibitorFRAX 597
Potent group I PAK inhibitorMRT 68921 dihydrochloride
Potent ULK inhibitor; inhibits autophagyAM 2394
Potent glucokinase activator; orally bioavailableeCF 309
Potent mTOR inhibitorPF 3758309 dihydrochloride
Potent PAK4 inhibitor; orally availableAZ Dyrk1B 33
Potent and selective Dyrk1B kinase inhibitorPF 06409577
Potent and selective allosteric activator of AMPKPerifosine
PKB/Akt inhibitor; also modulates Kv2.1 currentRAF 265
Raf kinase and VEGFR-2 inhibitorCZC 25146
Potent LRRK2 inhibitorRo 3280
Potent and selective PLK1 inhibitorRMM 46
MSK/RSK family kinase inhibitorLTURM 34
Potent DNA-PK inhibitorMLi-2
Potent and selective LRRK2 inhibitorLTURM 36
PI 3-kinase δ inhibitorPI 3065
Potent and selective PI 3-kinase p110δ inhibitorAZ PFKFB3 67
Potent and selective PFKFB3 inhibitorSTOCK2S 26016
Lysine deficient protein kinase (WNK) signaling inhibitor
April 22 - 26, 2017
Chicago, IL, USA